Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
WEHI-539 hydrochloride sale We find that the interaction of
2024-09-02

We find that the interaction of NSF and SNAP is critically involved in NMDAR-induced PICK1 unclustering. The binding of SNAP to NSF increases the ATPase activity of NSF, which is known to be essential for the unbinding of PICK1 from GluR2 (Hanley et al., 2002). Disruption of the association between
-
br Conflict of interest statement br Acknowledgement br Intr
2024-09-02

Conflict of interest statement Acknowledgement Introduction Lipoxygenases (LOs) are enzymes catalyzing the positional as well as stereo-specific introduction of molecular oxygen into 1,4-pentadiene structures found in unsaturated fatty acids such as arachidonic VKGILS-NH2 or linoleic acid [
-
boc boc One of the specifications of the NIA AA research fra
2024-09-02

One of the specifications of the NIA-AA research framework was that it boc boc be applicable in two distinct research contexts—interventional trials and observational research. In many if not most modern AD interventional trials, individuals are selected for inclusion with the aid of biomarkers. Th
-
Here we have used transcriptome analysis of primary
2024-09-02

Here, we have used transcriptome analysis of primary neonatal rat cardiomyocytes treated with either the ETR agonist endothelin-1 or the α1-AR agonist phenylephrine to assess differences in their respective signalling networks, and further probed these differences using a panel of fluorescent resona
-
itk inhibitor Pituitary adenylate cyclase activating polypep
2024-08-31

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as
-
br Roles for GMF in Endocytic Traffic In addition to
2024-08-31

Roles for GMF in Endocytic Traffic In addition to its roles in cell migration, GMF regulates actin-dependent endocytosis in yeast and mammals 13, 14, 50, and promotes the turnover of focal adhesions in immune Cyclophosphamide 42, 51. Vinculin, a central component of focal adhesions that anchors c
-
br ACh and ER tests hereafter Spasm
2024-08-31

ACh and ER tests hereafter Spasm provocation tests have self-limitations to document coronary artery spasm during daily life. In the past reports, ST elevation was reproducible in some patients with variant bryostatin by the administration of ACh or ER. However, we now employ the ER and ACh spas
-
Whereas more research is needed to
2024-08-31

Whereas more research is needed to identify the precise mechanism by which FIN exerts its antidyskinetic effect, the atrial natriuretic peptide receptor that it can negatively modulate dopaminergic transmission is also supported by our previous findings. Indeed, we have previously shown that FIN co
-
br Materials and methods br
2024-08-31

Materials and methods Results Discussion Proteomics analyses generate mountains of data, expression information for hundreds or thousands of proteins in a single experiment (Wojcik and Schächter, 2000). Recently proteomics and bioinformatics provide new understandings about the processes in
-
br Discussion Herein we demonstrate that mice deficient in L
2024-08-31

Discussion Herein, we demonstrate that mice deficient in L-12/15 LO are more sensitive to 3-NP-induced toxicity although a substantial individual variability in striatal lesion size in response to 3-NP in both genotypes was observed. This variability is not atypical; several studies demonstrate s
-
Enhancers are short regions of DNA that are bound by
2024-08-31

Enhancers are short regions of DNA that are bound by DNA-binding proteins (TFs) to increase the likelihood of a particular gene to be expressed. Importantly, enhancers can be identified, and classified, by their patterns of chromatin accessibility and of enrichment in certain histone modifications.
-
Based on structure activity relationship of several SARM
2024-08-30

Based on structure activity relationship of several SARM templates, Ligand Pharmaceuticals chose LGD2226 as their first clinical candidate (Miner et al., 2007). Although LGD2226 demonstrated myo- and osteo-anabolic activity and maintenance of sexual function in various preclinical models, the develo
-
In our sequential model for tau and
2024-08-30

In our sequential model for tau and Aβ deposition, we included the tau deposition in the medial temporal neurokinin 1 receptor in the absence of Aβ deposition, which is a pathological definition of primary age-related tauopathy (PART). Although the tau pathologies in PART and AD are almost identica
-
Detailed analysis of the dose dependence of A
2024-08-30

Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory
-
PF is orally bioavailable and has appropriate pharmacokineti
2024-08-30

PF-06409577 is orally bioavailable and has appropriate pharmacokinetic properties for use in rodents, allowing us to evaluate its impact on lipid and cholesterol biosynthesis in vivo (Cameron et al., 2016). PF-06409577 lowered the incorporation of 14C-acetate into hepatic lipids in vivo in a dose de
15801 records 92/1054 page Previous Next First page 上5页 9192939495 下5页 Last page